Company to Present Interim Analysis Secondary Endpoint Data Including Progression-free Survival from Phase III TIGeR-PaC Study, a Multi-center Open-label Study Evaluating RenovoGem to Treat Locally
Company to Present Interim Analysis Secondary Endpoint Data Including Progression-free Survival from Phase III TIGeR-PaC Study, a Multi-center Open-label Study Evaluating RenovoGem™ to Treat. | May 25, 2023
RenovoRx Presenting Phase III Clinical Trial Interim Analysis Data of the TIGeR-PaC Study at American Association for Cancer Research Annual Meeting Underway in Orlando, Florida streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
RenovoRx (RNXT) Presenting Phase III Clinical Trial Interim Analysis Data streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Ms. Gentry, an Industry Expert in Clinical Trials Management, Adds Valuable Leadership Experience to Advance Studies in Cancer Treatment
. | April 11, 2023